Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of once-daily GSK573719 + GW642444 versus components and placebo in COPD
NL-OMON36160Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoints: Change from baseline in trough FEV1 on Day 169 and Safety. Started Apr 2011; status: active, not recruiting.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON36160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36160.